3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 2/3
2
Phase 4
1
Phase 3
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Melanoma
1
Glioma
1
Brain Neoplasms
1
Interventions
Cisplatin
22
pembrolizumab
17
Drug Therapy
16
Carboplatin
15
Paclitaxel
12
Gemcitabine
12
Dexamethasone
12
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
venetoclax
8
atezolizumab
8
Pemetrexed
8
Oxaliplatin
8
Docetaxel
8
Specimen Handling
7
Radiotherapy
7
Nivolumab
7
Cyclophosphamide
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
Methotrexate
6
durvalumab
5
blinatumomab
5
Cytarabine
5
Androgen Antagonists
5
tislelizumab
4
spartalizumab
4
pertuzumab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
entrectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled